The landmark SELECT trial demonstrated that weekly semaglutide 2.4 mg reduces major cardiovascular events by 20% in people with obesity or overweight and established heart diseaseeven in those without diabetes.[1] This finding represents a paradigm shift in cardiovascular prevention, as it's the first time a weight-loss medication has been proven to directly reduce heart attacks, strokes, and cardiovascular deaths
Bifidobacterium lactis strains in particular have been studied for improving stool frequency and consistency in adults with functional constipation
Antioxidants & redox signaling , 28 18, 1652-1668
Il corriere ritira le spedizioni entro le 15.00, pertanto tutti gli ordini che ci pervengono dopo questo orario verrano evasi nel giorno successivo
Study participants injected themselves weekly with semaglutide, beginning with a dose of 0.25 mg and increasing to 1 mg at week 4, which is the dose prescribed for diabetes, Lake said
Dont treat it like a replacement